Q1 2025 Johnson & Johnson Earnings Call
Yeah.
Speaker Change: Good morning, and welcome to Johnson <unk> Johnson's first quarter 2025 earnings conference call.
Speaker Change: All participants will be in listen only mode until the question answer session of the conference.
Speaker Change: This call is being recorded if anyone has any objections you may disconnect at this time.
Speaker Change: If you experience technical difficulties during the conference you May press star zero to reach the operator.
Jonathan Johnson: Now I'd like to turn the conference call over to Jonathan Johnson, you may begin.
Jonathan Johnson: Hello, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson <unk> Johnson welcome to our company's review of business results for the first quarter of 2025, and our updated financial outlook, a few logistics before we get into the details.
Jonathan Johnson: As a reminder, you can find additional materials, including today's presentation and associated schedules on the Investor Relations section of the Johnson <unk> Johnson website at Investor Dot J&J dotcom.
Jonathan Johnson: Please note that this presentation contains forward looking statements regarding among other things the company's future operating and financial performance market position and business strategy.
Jonathan Johnson: You are cautioned not to rely on these forward looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected.
Jonathan Johnson: Description of these risks uncertainties and other factors can be found in our SEC filings, including our 2024 Form 10-K, which is available at Investor got J&J Dot com and on the Sec's website. Additionally.
Jonathan Johnson: Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships moving.
Jonathan Johnson: Moving to today's agenda Joaquin Duato, our chairman and CEO will open with a few comments on our performance and key catalysts for the company.
Speaker Change: John Reed, our executive Vice President innovative medicine, R&D well highlight recent data from select assets I will then review the first quarter sales and P&L results.
Speaker Change: Joe Walk our CFO will then close by sharing an overview of our cash position capital allocation priorities and guidance for 2020 five.
Speaker Change: Jennifer Taubert Executive Vice President worldwide, Chairman innovative medicine, and Tim Schmidt Executive Vice President worldwide, Chairman Med Tech will be joining us for Q&A joined.
Joaquin Duato: To ensure we provide enough time to address your questions. We anticipate the webcast will last slightly over 60 minutes with that I will now turn the call over to Joaquin.
Joaquin Duato: Thank you James Hello, everyone.
In the first quarter, we delivered strong operational sales growth of 4.2% across our business.
Joaquin Duato: Our Q1 performance reinforces my confidence in our 2025 guidance and reflect the strength of Johnson <unk> Johnson's uniquely diversified business with year over year sales increases in both our email base, you've maybe seen a med tech sectors no.
The company has de lever of growth through the first year of losing exclusivity for a multi billion dollar problem.
Joaquin Duato: In our case still later on jet that'd be say exactly what we are doing.
Joaquin Duato: Resiliency is a testament to what makes US unique we are not just a pharmaceutical company or a med Tech company. We are a healthcare company innovating across the full spectrum of disease.
Joaquin Duato: Our consistent strong performance is a testament to our capabilities across commercial R&D and supply chain. It is also a reflection of our strength in execution, which you can see in our quarterly it can be sold.
Joaquin Duato: We have described 2025 as a catalyst year you decide year that will set us up for accelerated growth through the second half of the decade and beyond.
Joaquin Duato: In Q1, the power of our portfolio pipeline was on full display.
Joaquin Duato: In innovative maybe seem we delivered four 2% operational sales growth. Despite an approximate 810 and 10 basis points headwind from Este Lauder, we see living in key brands growing double digits.
Joaquin Duato: We saw our third consecutive quarter of sales above $3 billion that our sellers continues to set the standard in multiple myeloma, we saw another quarter of over 20% growth.
Joaquin Duato: In fact, just last week, we expanded our water that selects indication in Europe with the approval or thought that as Alex based Watson, who played the regimen for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.
Joaquin Duato: It is further proof of the impact of these maybe seen which together we've got a big deep television and take Bailey is changing the conversation from treating to progression to treating to cure.
Joaquin Duato: Are there significant oncology portfolio advancements in Q1 included phase three data presented at El Sissi last month, showing <unk> plus less glues extended overall survival by more than one year versus the current standard of care in first line.
Joaquin Duato: And your father mutated lung cancer.
Joaquin Duato: Last week, the European Commission approved subcutaneous private demand in combination with less crews for the treatment of Egfr mutated non small cell lung cancer.
Joaquin Duato: This was an important milestone for patients a subcutaneous right bromine reduces administration time from hours to minutes.
Joaquin Duato: I want a speed issue any sport arrive at about plus less crews to become the new standard of care for these patients and you can see our progress in Q1.
Joaquin Duato: In immunology, we are seeing the impact of the rimfire, yes entry into inflammatory bowel disease, we thought about launch in ulcerative colitis, helping accelerate operational sales growth to 20%.
Joaquin Duato: With our recent FDA approval in Crohn's disease are more.
Joaquin Duato: We're confident than ever that these blockbuster drugs will become deagle stand at Ford IBD patients and $10 billion plus product.
Joaquin Duato: Turning to Mystic in Q1, we delivered four volume, 1% operational sales growth with strong performance in our recently acquired cardiovascular businesses.
Joaquin Duato: I'm at a show wave as well as in surgical vision and wound closure.
Joaquin Duato: In addition to their contribution to meet their growth albumin and <unk> continued to meet deal model expectations, and both announced important portfolio milestones this quarter.
This included updates to the American College of Cardiology, and the American Heart Association guidelines for our Impella heart pump, which space or maybe you didnt from dangerous choke Dio was upgraded from class B to class eight and <unk>.
Joaquin Duato: In short wave the team launched the first of its sky javelin Bedford IV for the treatment of difficult to cross lesions in peripheral artery disease.
Joaquin Duato: In electrophysiology would've assumed U S body pulse cases and to date, we have completed more than 5500 cases globally.
Joaquin Duato: Turning to surgery, we recently announced we have started ottava clinical trials with a procedure that supports submission for U S. F D. A de Novo, Indiana surgery with an indication for multiple upper abdomen procedures.
Joaquin Duato: This is an important milestone as we continued to strengthen our presence in robotic surgery.
Joaquin Duato: John our existing portfolio and pipeline, we also fortified our leadership as an innovation powerhouse with dual may your announcements.
Joaquin Duato: In March we announced our commitment to invest more than $55 billion in the U S. Over the next four years in manufacturing R&D and technology. These represents a 25% increase in investment compared to the previous four years.
Joaquin Duato: It builds upon the companies already elevated commitment to the U S economy, while expanding our capacity to manufacture our next generation <unk> NAND devices for patients in America and around the world.
Joaquin Duato: The investment includes four plant Newman, who factoring facilities, the first of which broke ground last month in North Carolina.
Joaquin Duato: And at the beginning of April we announced the completion of our acquisition of intracellular therapies, which extend Georgetown enjoying some industry leading portfolio in central nervous system disorders with the addition of Cup light that we have expanded our lineup of therapies with at least $5 billion.
Plus potential in peak year sales further solidify in sales growth above analyst expectations now through the rest of the decade.
Joaquin Duato: Turning to the talc bankruptcy ruling as we shared a few weeks ago, we wanted to turn to the tort system well, we expect continual success in mitigating these meritless claims.
Joaquin Duato: In terms of next steps, we will immediately pursue our motion spending in the multi district litigation to exclude plaintiffs experts known as the Daubert Challenge finally as announced this morning, we increased our dividend for the 16th consecutive year, which we.
Joaquin Duato: We know it's important to our shareholders.
Joaquin Duato: We had a strong start to 2025 and I'm looking forward to sharing many more successes throughout the year recognizing that there have been many important milestones and data readouts in the quarter I will now pass the call to John Reed for an innovative maybe seen R&D update.
John Reed: Thank you Joachim.
Speaker Change: I'm excited to share a few highlights from our industry, leading innovative medicine pipeline that occurred throughout the quarter.
John Reed: With the successful acquisition of intracellular.
John Reed: Want to focus on cap lighter a remarkable medicine with balanced pharmacology that delivers robust efficacy combined with a favorable tolerability profile for neuropsychiatric disorders.
John Reed: Kept lyda is already approved for the treatment of schizophrenia and is the only medicine approved for the treatment of depression in both bipolar one and two as either monotherapy or adjunctive therapy.
John Reed: On this slide we're sharing data for major depressive disorder.
John Reed: <unk> very impressive and consistent improvements in the standard depression, scoring metric mantras in both phase III studies that served as the basis for submission of the supplemental new drug application to the F. D. A.
John Reed: We anticipate approval of cap light of later this year as an adjunctive treatment for major depressive disorder, representing the largest of the indications for novel antidepressant drugs today.
John Reed: Turning to oncology, we are so excited about our recent overall survival data for Reiber ban plus last clues in first line non small cell lung cancer harboring EGF receptor gene mutations.
John Reed: Non small cell lung cancer is the most prevalent type of lung cancer, making up about 85% of lung cancer diagnoses.
John Reed: Sadly less than 20% of people diagnosed with this form of the disease are alive. After five years and only a fraction live long enough to try a second treatment.
John Reed: That's why it is so important to use the best treatment first.
John Reed: In a head to head study against today's standard of care are reiber band plus last clues regimen improved overall survival by more than a year with the Kaplan Meier survival curves continuing to separate at 37.8 months median follow up.
John Reed: With reiber bands Triple mechanism of action.
John Reed: We're looking to reset the standard five year survival expectations in a never before seen way in simplest terms.
John Reed: We are giving patients more hope that they may live to celebrate another birthday anniversary or other important family of M. A truly practice changing achievement.
John Reed: Now moving on to immunology I draw your attention to the recent FDA approval of trim fire in Crohn's disease, our fourth indication for trim fire.
John Reed: <unk> is currently the only IL 23 inhibitor with the flexibility of subcutaneous administration for both induction and maintenance dosing for the treatment of Crohn's disease, which means patients can start their treatment by self administering with results.
John Reed: As rapid and robust is receiving the IV in a clinic or a doctor's office.
John Reed: Additionally, in a recent head to head study in adult patients with moderately to severely active crohns disease.
John Reed: <unk> demonstrated superiority versus still Laura in all pooled endoscopic endpoints.
John Reed: As the only dual acting IL 23 inhibitor trim buyer neutralizes IL 23, while also binding to <unk> 64 in immune cells that produce IL 23, thus localizing trimmed by a REIT at the source of inflammation.
John Reed: Trimpe via continues to offer an exceptional solution for patients struggling with inflammatory bowel disease.
John Reed: Lastly, highlighting some of our latest data for our investigational oral IL 23 pathway inhibitor I co true Kendra, we are aiming to redefine the standard of care for people living with plaque psoriasis.
John Reed: I co drew Kendra is the first and only targeted oral peptide that selectively blocks the IL 23 receptor.
John Reed: In two placebo controlled phase III studies.
John Reed: I coached kindred demonstrated impressive complete skin clearance and a favorable safety profile in a once daily pill.
John Reed: Our phase III data demonstrated that nearly half of adult patients and three quarters of adolescents with moderate to severe plaque psoriasis treated with <unk> achieved completely clear skin by week 24.
John Reed: We also reported that a cultural kendra.
John Reed: Keep the pre specified endpoints in additional phase III psoriasis studies, comparing our molecule head to head with the most commonly prescribed <unk> two inhibitor.
John Reed: Those data will be shared at an upcoming medical Congress.
John Reed: Looking forward.
Speaker Change: We are initiating the first ever head to head study seeking to demonstrate the superiority of a pill echo true kinross compared to an injectable biologic still Laura.
Speaker Change: Moderate to severe plaque psoriasis, representing an important step forward in psoriasis research.
Speaker Change: As a reminder, we intend to file a cultural kendra.
Speaker Change: For approval later this year.
Speaker Change: Finally beyond psoriasis, we recently announced positive topline results from anthem, you see our phase <unk> study of <unk> in adults with moderate to severe ulcerative colitis.
Speaker Change: That study show that <unk> achieved impressive clinical remission rates combined with a favorable safety profile again dosed as a once daily pill.
Speaker Change: With all this progress you can understand why we continue to be excited about the potential of Iqos Kendra to transform the treatment paradigm for patients battling with autoimmune diseases.
Overall across all our therapeutic areas, we are absolutely thrilled with the progress with our pipeline is made in the first quarter of this year and we are eager to report on another significant milestone schedule for the remainder of 2025.
Jeff: Now I will turn the call over to Jeff.
Jeff: Thank you John moving to our financial results unless otherwise stated percentages quoted represent operational results and therefore exclude the impact of currency translation.
Jeff: Starting with Q1 2025 sales results.
Jeff: Worldwide sales were $21 $9 billion for the quarter sales increased 4.2%. Despite an approximate 470 basis point headwind from Stella.
Jeff: In the U S was five 9% and 2.1% outside of the U S.
Jeff: Worldwide growth was positively impacted by 90 basis points due to the acquisition and divestitures.
Jeff: Turning now to earnings for the quarter net earnings were $11 billion and diluted earnings per share was $4.54 versus diluted earnings per share of one dollar and 34 cents a year ago, primarily driven by the reversal of $7 billion related to the <unk>.
Jeff: <unk> settlement proposal.
Jeff: Excluding after tax intangible asset amortization expense and special items for both periods adjusted net earnings for the quarter were $6 $7 billion and adjusted diluted earnings per share was $2.77 representing increases of 1.9 per se.
Jeff: And 2.2%, respectively compared to the first quarter of 'twenty 'twenty four we're proud to deliver bottom line growth. Despite the loss of exclusivity of fill Ara and the impact of part D redesign.
Jeff: I'll now comment on business sales performance in the quarter.
Jeff: Beginning with innovative medicine.
Jeff: Worldwide sales of $13 $9 billion increased four 2%, despite an approximate 810 basis point headwind from Stella.
Both in the U S was six 3% and 1.5% outside of the U S.
Jeff: Starting with oncology <unk> growth was 22.5% primarily driven by continued share gains of approximately three points across all lines of therapy and approximately five points in the frontline setting as well as market growth.
Jeff: Perfect. He achieved sales of $369 million and growth of over 100% driven by share gains and capacity expansion. This reflects sequential growth of 10, 5% as we continue to expand outside of the U S Tech valley until they growth with 15%.
Jeff: <unk> and 52%, respectively, reflecting strong launches in the relapsed refractory setting.
Jeff: Asian demand remains strong despite continued adoption of longer dosing intervals.
Jeff: Our leader continued to deliver strong growth of 14.6%. Despite the impact of part D redesign, primarily driven by share gains and market growth reiber.
Jeff: <unk> plus last clues continued its strong launch trajectory with sales of $141 million and growth over 100%.
Jeff: Within immunology transpire delivered growth of 21% despite the impact of part D redesign driven by share gains and market growth across all indications, including our newly launched indication and alterative colitis stellar.
Jeff: The Lora declined 32.3% driven by the impact of Biosimilar competition and part D redesign.
As a reminder, remicade and attempt to need distribution rights in Europe were returned in Q4. This positively impacted results in the quarter and is anticipated to continue for the remainder of the year.
Jeff: <unk> sales also include a one time patient mix benefit in the U S and.
Jeff: In neuroscience <unk> growth of 42, 9% was driven by increased physician and patient demand.
Jeff: Finally, other assets that were impacted by part D. Redesign include and Vega of long acting Injectables, which declined 13.5%.
Jeff: Pulmonary hypertension, which declined 1.2% and was partially offset by market growth and share gains and they're alto, which increased by 33% and also included a one time patient mix benefit.
Jeff: I'll now turn your attention to Mantech worldwide sales of $8 billion increased four 1% with growth of five 1% in the U S and 3% outside of the U S.
Jeff: Acquisitions, and divestitures had a net positive impact of 280 basis points on worldwide growth 420 basis points in the U S and 120 basis points outside of the U S.
Jeff: Underlying med Tech performance was driven by commercial execution and strength of new products, partially offset by several one time events disproportionately impacting orthopedics. In addition to continued competitive P F a pressures and electrophysiology and headwinds in China.
Jeff: Results were negatively impacted by approximately 210 basis points worldwide 240 in the U S and 180 outside of the U S. Due to these one time events.
Jeff: In cardiovascular electrophysiology growth was roughly flat versus prior year, driven by lapping of prior year inventory dynamics in Asia impacting worldwide results by roughly 310 basis points and competitive PSA ablation catheter pressure.
Jeff: This was mostly offset by global procedure growth, new product uptake and commercial execution.
Speaker Change: Abby Nomad delivered growth of 14% driven by strong growth in all regions and continued adoption of Impella five five and then palace C. P technology.
Speaker Change: Cardiovascular results also included $258 million associated with the acquisition of Shockwave as a reminder, we will lap the acquisition benefit at the end of May.
Speaker Change: Envision contact lenses and other grew two 7% driven by continued strategic price actions and strong performance in the Accu view Oasis, one day's family of products.
Speaker Change: Surgical vision growth of six 2% was driven by our recent innovations Technip Odyssey, PRC and I hands as well as commercial execution, partially offset by competitive pressures in the U S. So.
Speaker Change: Surgery grew 1.1% with divestitures negatively impacting results by approximately 180 basis points performance was driven primarily by commercial execution and the continued strength and adoption of new products across the mine closure and bio surgery.
Speaker Change: This was partially offset by competitive pressures in energy and endo cutters as well as the negative impact of China V. P.
Speaker Change: Given the disproportionate impact of the one time events to orthopedics I'd like to draw your attention to this additional side.
Speaker Change: The Phoenix declined three 1%, primarily driven by the lapping of a onetime revenue recognition timing change related to certain products across all platforms in the U S fewer selling days and revenue disruption from the previously announced orthopedics transformation.
Speaker Change: These one time events negatively impacted worldwide orthopedics growth by approximately 480 basis points.
Speaker Change: 650 basis points in the U S and 210 basis points outside of the U S. This was partially offset by success of new product launches and commercial execution now.
Speaker Change: Now turning to our consolidated statement of earnings for the first quarter of 2025.
Speaker Change: I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year.
Speaker Change: Cost of products sold Deleveraged by 320 basis points, driven by unfavorable transactional currency and product mix, primarily due to the decline is still Ara and innovative medicine as well as the fair value step up and the amortization associated with the Shockwave acquisition in Med Tech.
Speaker Change: Selling marketing and administrative expenses improved to 130 basis points, driven by operating spend management and phasing of investments primarily an innovative medicine.
Speaker Change: Research and development expenses leveraged by 190 basis points, primarily driven by portfolio progression towards commercialization and phasing of investments in innovative medicine, partially offset by investments associated with the recent acquisitions of Shockwave N V wave in Med Tech.
Speaker Change: Interest income and expense was a net income of $128 million as compared to $209 million in the first quarter of 'twenty 'twenty, four primarily driven by higher interest rates paid on higher average debt balances.
Speaker Change: Other income and expense was a net income of $7 $3 billion compared to an expense of $2 $4 billion in the prior year driven by the 7 billion dollar Talc reserve reversal in the first quarter of 'twenty 'twenty five and the $2 7 billion dollar talk settlement proposal recorded during the first.
Order of 'twenty 'twenty four.
Speaker Change: Regarding taxes in the quarter, our effective tax rate was 19, 3% versus 12, 4% in the same period last year, primarily driven by the tax effect of the reversal of the talc settlement accrual.
Speaker Change: Excluding special items, the effective tax rate was 16.3% versus 16, 5% in the same period last year.
Speaker Change: I encourage you to review our upcoming first quarter 10-Q filing for additional details on specific tax related matters.
Speaker Change: Lastly, I'll direct your attention to the box section of the side, where we have also provided the company's income before tax net earnings and earnings per share adjusted to exclude the impact of intangible amortization expense and special items now.
Speaker Change: Now, let's look at adjusted income before tax by segment for the quarter.
Speaker Change: This quarter and to continue our efforts of increased financial transparency, you will find GAAP to non-GAAP reconciliations by segment in the supplemental schedules of our press release.
Speaker Change: Innovative medicines margin declined from 42, 9% to 42.5%, primarily driven by unfavorable transactional currency and product mix and cost of products sold and part D redesign, partially offset by operating leverage Med Tech margin declined from 26.
Speaker Change: 0.4% to 25, 9%, primarily driven by R&D and selling marketing and administrative investments associated with the recent acquisition of Shockwave N V wave as a result adjusted income before tax for the enterprise as a percentage of sales decreased from <unk>.
Speaker Change: 36, 8% to 36, 6%. This concludes the sales and earnings portion of the call and I will now turn the call over to Joe.
Joe Walk: Hello, everyone and thank you for joining us today, thanks, Jessica not just for the transition now, but also for how well you have led the investor relations function in the past few years the investment community will Miss you, but we look forward to seeing you in the lead finance role for innovative medicine.
Joe Walk: Our first quarter results demonstrate the strength and reliability of Johnson <unk> Johnson's diversified business model innovative medicine achieved robust growth in the face of still are a biosimilar entrants and we advanced our pipeline attaining significant clinical and regulatory milestones.
In Med Tech as indicated in January we anticipated pockets of challenge early on and are planning for higher second half growth in those areas of our business. The team is focused on commercial execution and accelerating the recently launched products to deliver med techs commitments that are included in the company's full year guidance.
Joe Walk: The recent acquisitions of Albion met in Shockwave continue to expand our presence in higher growth markets.
Joe Walk: In addition, we continue to take steps to improve med Tech's future margin profile implementing a restructuring program designed to simplify and focus the operations of our surgery business similar to what we launched in orthopedics in 2023.
Joe Walk: Focusing on portfolio renewal, we plan to exit certain non strategic product lines globally, and optimize select sites across the network.
Joe Walk: We anticipate some modest short term revenue disruption in surgery of approximately $250 million in total over the next two years, but these actions will improve our ability to accelerate growth and enhanced profitability.
Joe Walk: Program is expected to be completed in 2027 with cost estimated at approximately $900 million.
Joe Walk: Let's now turn to cash and capital allocation.
Joe Walk: We are pleased with free cash flow generation in the quarter of approximately $3 $4 billion.
Joe Walk: We ended the first quarter with $38 $8 billion of cash and marketable securities and $52 $3 billion of debt for a net debt position of $13 $5 billion. It is important to note that cash and net debt were favorably impacted by approximately $14 billion of cash held in anticipation of the intracellular.
Joe Walk: <unk> acquisition, which closed on April 2nd taking this into consideration net debt would have been approximately $27 5 billion.
Joe Walk: Investment in innovation remains the highest priority in our capital deployment and during the first quarter, we invested more than $3 billion in research and development approximately 15% of sales.
Joe Walk: We also remain committed to returning capital directly to shareholders, we recognize the value investors place on our dividend and we were pleased to announce today that our board of directors authorized a four 8% increase marking our 63rd consecutive year of dividend increases.
Joe Walk: The intracellular therapies acquisition bolsters, our neuroscience portfolio and we maintain a disciplined approach to inorganic growth focusing on acquisitions and partnerships that align strategically and offer value creation.
Speaker Change: As noted in our talc investor call and following up on some of what Keens earlier comments, we reversed $7 billion of the reserve previously held for the bankruptcy plan.
Speaker Change: This litigation has not and we foresee will not impact our ability to execute upon our capital allocation priorities to appropriately manage our business.
Speaker Change: Let's now discuss our full year guidance for 2025.
Speaker Change: We are increasing our operational sales guidance for the full year by $700 million to reflect the addition of cap lighter following the completion of the intracellular acquisition.
Speaker Change: Therefore, we now expect operational sales growth for the full year to be in the range of three 3% to four 3% with a midpoint of $92 billion or three 8%.
Speaker Change: Excluding the impact from acquisitions and divestitures, we are maintaining our adjusted operational sales growth to the range of 2% to 3% compared to 2024.
Speaker Change: As you know, we don't speculate on future currency movements and last quarter, we utilize the euro spot rate relative to the U S dollar of 1.04.
Speaker Change: Last week, the euro spot rate relative to the U S. Dollar was 1.11, we estimate an incremental positive foreign currency impact of $1 $1 billion versus previous guidance, resulting in a full year headwind of $600 million.
Speaker Change: As such we now expect reported sales growth between 2.6% to three 6% with a midpoint of $91 $4 billion or three 1%.
Speaker Change: Turning to other notable items on the P&L.
Speaker Change: We are maintaining our guide of operating margin improvement by 300 basis points versus 2024.
Speaker Change: This improvement takes into consideration the dilution from the intracellular transaction as well as what we know today about the impact of tariffs on our business.
Speaker Change: We now project net interest expense between $100 million and $200 million, primarily driven by financing costs associated with the intracellular acquisition.
Speaker Change: Other income is anticipated to be in the range of $1 billion to $1 $2 billion, a slight increase versus previous guidance.
Speaker Change: Despite 25 cents deletion from the intracellular acquisition and including the impact of tariffs based on what is in place today. We are pleased to be able to maintain our adjusted reported earnings per share guidance of six 2% at the midpoint for a range of $10 50 to $10.70, partially aided by the reduced FX impact.
Speaker Change: Yeah.
Speaker Change: I'll now provide some qualitative considerations on phasing for your models.
Speaker Change: We continue to expect both innovative medicine in med tech operational sales growth to be higher in the second half of the year versus the first half.
Speaker Change: Regarding innovative medicine, we maintained the assumption that the impact of the law of Biosimilar competition will accelerate throughout the year similar to Humira erosion curve, which is still our proxy with the additive impact of part D redesign.
Speaker Change: The impact of part D redesign on effective products as a percent of sales will.
Speaker Change: It will be consistently applied throughout the year aligned with how we traditionally account for similar discount or rebate programs.
Speaker Change: Naturally we expect a greater benefit from our newly launched products as the year progresses.
Speaker Change: Regarding med Tech, we expect normalized procedure volume and.
Speaker Change: Seasonality and of course, we anniversary the Shockwave acquisition at the end of May.
Speaker Change: We anticipate our newly launched products to build throughout the year with the relaunch of our pulse in the U S. The introductions of dual energy S. T. S F in the E U.
Speaker Change: This unity.
Speaker Change: <unk> spine and technical Odyssey.
Speaker Change: Lastly, this slide highlights the one time prior year P&L items that should be taken into quarterly consideration for your models.
Joaquin Duato: Beyond our financial commitments and what Joaquin and John mentioned, we are excited for the pipeline progress planned for the remainder of 2025.
Joaquin Duato: An innovative medicine. This includes expected approvals and nipper calamos for generalized myasthenia gravis subcutaneous.
Joaquin Duato: Subcutaneous reiber van for non small cell lung cancer in the U S trumpf.
Joaquin Duato: <unk> via subcutaneous induction for ulcerative colitis, and cap Lidar for adjunctive major depressive disorder.
Joaquin Duato: We continue our rolling submission of Tar 200 in non muscle invasive bladder cancer and anticipate filing a coach for kindred and psoriasis.
Joaquin Duato: And planned data Readouts for reiber, van and head and neck cancer, and a cultural Kinder and ulcerative colitis as well as head to head data versus citic too in psoriasis.
Joaquin Duato: In Med Tech, we continue to make progress with clinical trials for ottava robotic surgical system and across our cardiovascular portfolio, including heart recovery with Impella ECP submission and circulatory restoration with javelin and Shockwave E eight launches.
Speaker Change: This progress will bode well for financial performance for the balance of this decade in fact building on John's earlier discussion on our innovative medicine pipeline and what I, just outlined I'd like to revisit and update our slide that we shared at our enterprise business review in late 2023.
Speaker Change: In that slide you may recall, we highlight the key assets in our portfolio that we expect it to drive long term growth and projected higher revenue than street estimates.
Speaker Change: We've been pleased to see some estimates have been raised since the 2023 enterprise business review and now I'd like to walk you through some of our current thinking on our pipeline potential to show, where we see even more upside.
Speaker Change: Based on current 2027 Street estimates or projections are at least two times higher for <unk>, plus last clues and at least 50% higher for <unk>.
Speaker Change: One asset that we didn't highlight in this look back in 2023 was trimmed fire. However, given recent regulatory approvals for inflammatory bowel disease. We now see sales for sure in fire at least 25% higher than current Street estimates.
Speaker Change: When looking ahead to 2028, we anticipate sales for our Intervascular drug releasing system previously referred to as tourists to be at least three times higher than current street estimates and new to the chart I coach Kinzer, our targeted oral peptide to be at least two times higher to be balanced analyst estimates are.
Speaker Change: Still a bit more optimistic than our own estimates on nipper, <unk> and 'twenty 'twenty seven however.
Speaker Change: However, we do anticipate closing that gap after launch.
Speaker Change: We have even stronger conviction today and our growth opportunities than at the enterprise business review as we've reached new milestones with each of these medicines and importantly, we expect all of these assets to achieve peak year sales beyond 2028 with further potential upside to street estimates in the outer years.
Speaker Change: Even after considering risk adjustments for unapproved products that you may apply hopefully you will also conclude there was additional value to your outlooks.
Speaker Change: In summary, it was a solid start to the year Johnson <unk> Johnson's diversified business model uniquely positions us to tackle the headwinds in 2025 deliver on our financial commitments and advance our pipeline to create long term sustainable value for shareholders.
Speaker Change: Thank you and with that we're happy to take your questions. Kevin will you. Please provide instructions for those seeking to participate in the Q&A.
Speaker Change: Certainly went up a conducting a question and answer session, ladies and gentlemen, if you'd like to ask a question at this time. Please press Star then one on your telephone keypad.
Speaker Change: If you'd like to withdraw your question Press Star then two we ask you. Please limit yourselves to one question only.
Speaker Change: Our first question today is coming from Larry <unk> from Wells Fargo. Your line is that lives.
Speaker Change: Oh good morning, Thanks for taking the question and congrats on a nice quarter, Joe you talked about $400 million in tariffs in the 2025 guidance or about 14 cents by our math well what is that on an annualized basis and how are you thinking about being able to mitigate that over time can you can you pass along you know.
Speaker Change: Pass it along to customers or can you offset it by moving our production that thanks for taking the question yeah. Thanks, Larry and good to hear from you. So what's included in the $400 million and again that is primarily med tech tariffs at this point, it's based on the programs that have been announced and the timing that correlates with the.
Speaker Change: Those programs, so that would be inclusive of Mexico, and Canadian import tariffs that are not excluded out of U S. M. C. A it'll include two or some of them are very small degree some of the steel and aluminum tariffs that impact some of our products. It includes the China tariffs as well as the China retaliatory tariffs.
Speaker Change: That is probably the most substantial out of all the tariffs in terms of that $400 million and so just to maybe clarify for everybody that that as products of U S origin being shipped into China, and that's probably the most penalizing factor that $400 million I don't want to be Cavalier about that it's obvious.
Speaker Change: Lee.
Speaker Change: The program has been phased in as a partial year and then you have mostly this being captured as cost of goods. So it's going to sit on the balance sheet and inventory and be a relief through the P&L in future periods.
Speaker Change: So that's how that's how we're thinking of it in terms of mitigation strategies that I think you know across our entire business. We're very limited in terms of price leverage our whether it be on the med Tech side, there's a contractual agreements already in place and certainly very much precluded on the pharmaceutical side on current products that exist in terms of.
Speaker Change: Taking price increase.
Speaker Change: And I know Joaquin has a few thoughts regarding tariffs and maybe other mitigation factors and the supplier nature of our health care. Thank you Joe on thank you Lori for the question.
Speaker Change: Thinking about <unk>.
Speaker Change: I'm thinking specifically about pharmaceutical studies, there's a recent lottery why pharmaceutical study EFS zito.
Speaker Change: It's because <unk> can create disruptions in the supply chain leading to shortages.
Speaker Change: If what you want this to be manufacturing capacity in the U S. Both in Med Tech and in Pharmaceuticals, the most effective answer east no doubt.
But tax policy.
Speaker Change: As a matter fact seems set but I sense that 2017 tax reform.
Speaker Change: The investment in manufacturing both in Med Tech and in Pharmaceuticals has significantly increased.
Speaker Change: And when you think about our recent announcement of the <unk> $55 billion. So that if it makes four years at the completion of this investment plan essentially all what advance made it seems that that used in the U S will be manufacturer in the U S. So tax policy.
Speaker Change: He is a very effective tool to be able to build manufacturing capacity here in the U S. Both for mid tick.
Speaker Change: Myself because.
Speaker Change: I just wanted to follow up too you did ask about a full year impact and I will say I purposely ignored the question only because it would be way too speculative at this point as we know these tariffs are very fluid and the responsible action for US now is to quantify what we see the impact in 2026, and then see what happens with respect to.
Speaker Change: Does it lend itself to negotiations with other countries on what's actually in place as we get into the later part of 2025.
Speaker Change: Thank you. Your next question today is coming from Chris Schott from J P. Morgan Chase and company. Your line is now live.
Chris Schott: Great. Thanks, So much just had a question on gross margins in the quarter. It seems like these came in well below recent trends I'm trying to get a better understanding of the understanding of the drivers there and just the outlook going forward as we consider mix tariffs et cetera, and on the gross margin line. Thank you.
Chris Schott: Hey, Chris This is Joe Thanks for the question. So I won't say, it's a there's a two part answer to this one so specifically in the quarter when looking at first quarter of 2024, we obviously had the impact of us the Lora, which was a much higher gross margin product than our average product in our portfolio you had par.
Chris Schott: D, which is exclusively price, which is eroding margin and then you had some I would say transactional currency headwinds are one a favorable impact last year or in 2023 funneling into 2024, and then some unfavourably from last year's currency action I would expect moving forward.
Chris Schott: Based on some of the plans that we have you could expect that that 300 basis points to probably improve by a 3rd% to 50% and that would be inclusive of the tariffs that I just mentioned in Larry's question. The other thing I would say is I know you guys do a great job, but I think analysts were maybe a little bit optimistic.
Chris Schott: With respect to their outlook for gross profit given that we had just a lora and part D. Certainly communicated in the past I believe the consensus was taking gross margins up year over year and that one was probably a little bit of a mess, we probably could've done a better job explaining it.
Hayden: Thank you next question is coming from our side Hayden from Goldman Sachs. Your line is now live.
Hayden: Thanks for taking the question just going back to the stellar biosimilar erosion and the acceleration of the trajectory that we're going to see over the course of the AR.
Hayden: Are you able to provide any quantitative framing on your views as it relates to the extent to which you think this erosion gets smoothed out by the transition to other brands like some fire and other products. Thank you.
Hayden: Well good morning. Thanks, so much for the question. It is Jennifer so what we saw with tomorrow in the first quarter. It was definitely in line with our expectations for the product for the year and we continue to guide to the Humira two year erosion curve. Once there were multiple biosimilars as as really that bad.
Hayden: Model, there and make sure that you know are also including the additional impact of part D redesign if I can one.
Hayden: Additional point around still or are we take a look at the business. Overall. It was highlighted that we had four 2% growth across innovative medicine that included a negative 810 basis point impact from the Lora, if you exclude that from our business the remaining business the bulk 90%.
Hayden: Our business was actually growing at over 12%.
Hayden: Really demonstrating the strength of our overall business and with 11 key brands that were growing double digits. So yes, we've got Vista Lora L. O, we but the strength of the business is really coming through across all of our growth drivers.
Hayden: I would add to that.
Hayden: It is remarkable done in a year in which we are facing the headwind of the Este Lauder Biosimilars pod.
Hayden: The redesign.
Hayden: We are able to grow.
Hayden: Even in the first quarter.
Hayden: And that we are able to do eat like any other company to my knowledge because getting industry has shown it is a testament to the strength of our business to the DBS certification of our growth platforms.
Hayden: It gives me a strong belief that we're going to continue to delivered throughout the year.
Speaker Change: Jennifer just building on the focus on store Laura of courses to Lora begins to Sunset trim fire continues to rise. So you've seen the recent approvals in inflammatory bowel disease were trimmed by now is available is the only IL 23 class medicine for sub Q delivery and both of them.
Hayden: Duction and maintenance.
Hayden: We have generated additional strong data going head to head against a lora in a rigorous double blind study.
Hayden: Owning the superiority across all mucosal end point, so that's really disease modifying healing and then finally I would say you'll see later this year data in Psoriatic arthritis, where we've done a rigorous study looking at preservation of joint.
Hayden: Avoiding the joint erosion at least long term disability and what you'll see in those data when they are presented as a best in disease profile for trim buyer in Psoriatic arthritis. So really excited about the progress with the shrimp via the world's first selective IL 23 inhibitor.
Speaker Change: Thank you. Your next question today is coming from Daniela and tell people from UBS. Your line is now live.
Speaker Change: Hi, good morning, everyone. Thanks, so much for taking the question based on that for all that.
Speaker Change: However on parents in the ortho impact that was super helpful and that's where we're really going to Miss you, but congrats and good luck in your next role and just a quick question on you know and maybe this isn't it really a question I don't know, but I think it's still on the table and that we go into a recession.
Speaker Change: And I I'd love some color it as much as you can provide on how you guys think about your business and how are you.
Speaker Change: Recession proof it is and in what areas might be most at risk of underperforming.
Speaker Change: Relative to where we are today and our interaction and thanks so much.
Speaker Change: Hey, Danielle good to hear from you Yeah. It's a good question I think when we think about our business, though one thing we look to is certainly jobs reports in the U S and as of the most recent reports it seemed to be pretty healthy what was the reason we look at that is because it's a precursor as to who may have benefits in coverage for <unk>.
Speaker Change: Prescription medications as well as procedures inclusive of elective procedures, we have seen in times past when theres been a little bit of a recession at some of those elective procedures, maybe get delayed but they they don't get abandoned I'm thinking primarily within orthopedics, you know health care overall has proven to be.
Speaker Change: Well nothing is immune to a recession its been a little bit more recession proof than most other industries.
Speaker Change: And so we'll continue to monitor that but right now we feel good about the the standards of care that we're elevating on both the innovative medicine and med Tech side of the house overall cause scatter demand.
Speaker Change: <unk> remains solid and we feel good about the rest of the year regarding perceive loosen and use of pharmaceuticals, I don't know of any comments on that.
Speaker Change: Sure further to Joe's point, Danielle the category such as advanced I O L. A is a good precursor to really assessing the health of the economy.
Speaker Change: And so far we haven't seen any impact on the performance of our IL portfolio. In fact, we've seen the opposite when you look at the performance of R. R.
Speaker Change: Our I O L business on the back of the launch of both Texas Odyssey here in the U S and pure <unk> globally, we're seeing benchmark performances, and frankly, a turnaround of outperformance here in the in the U S with.
Speaker Change: With truly differentiated innovation and so so far.
Speaker Change: No major headwinds.
Speaker Change: Thank you. Your next question today is coming from turn split from Morgan Stanley. Your line is not a lot.
Speaker Change: Hi, good morning, Congrats on a quarter and thanks for taking the question Joe.
Speaker Change: Joe We heard your comments. This morning on the section 232, you know potential farm of tariffs being focused more towards generics API versus the complex branded biologic. So just wondering if that's based on your impression of the most likely outcome here or that's more just your speculation or hope for the outcome. Thank you.
Speaker Change: Let me let me take that question tenants myself. So we are analyzing the section 232, it was already announced pretty muesli. So it's something that we consider a normal that is going to happen on overall odd into my comments on <unk> four I think it's also important.
Speaker Change: <unk> got companies in health care, a part of it with the administration do look to mitigate.
Speaker Change: Some of the wounded abilities that exist today in our supply chain so as to avoid.
Speaker Change: Any continuity of supply effect. So it's important for us to partner with the administration and with the government and we plan to do it in this process to make sure that we have enough manufacturing capacity here in the U S to be able to do it is multiple scenarios.
Speaker Change: And Terence just to be clear that we want to be deferential to the administration and their process that is speculative just looking at the the pharmaceutical landscape and where you know national security interests may reside and what products. There are that those are delivered from so that that was really kind of our take.
Speaker Change: On it but we are working and engaging with the administration and being deferential to their process.
Speaker Change: Thank you. Your next question today is coming from Joanne Wuensch from Citibank. Your line is now live.
Joanne Wuensch: Good morning, and thank you for taking the question.
Speaker Change: This information is very helpful.
Joanne Wuensch: I wanted to pause for a second on the orthopedic sales.
Joanne Wuensch: And try to unpack how much of that is.
Joanne Wuensch: Yeah, which variable is there a way to quantify it and how do we think about the recovery in the back half of the year next year. Thank you.
Joanne Wuensch: John Thank you for the question and as we mentioned we've tried to provide as much transparency as possible to the significant impact of one timers in the quarter, which to your point to have disproportionately impacted the ortho business to the tune of roughly 480 basis points. There are three key drivers to the number one the lapping of prior year change in walking implants revenue.
Joanne Wuensch: Recognition.
Joanne Wuensch: Selling days and finally revenue disruption from the recent ortho transformation, which we announced in 2023. So when you actually look at our operational growth when accounting for those who would be closer to 2% now at the same time I will say.
Joanne Wuensch: We are we're not satisfied.
Joanne Wuensch: Our underlying performance was impacted by competitive pressures, primarily in spine and sports, which is partially offset by strong N. P is on commercial execution in categories like trauma shoulder and foot and ankle what gives us confidence in continued acceleration to the back half of the year is the incredible impact of truly differentia.
Joanne Wuensch: Innovation across our auto portfolio in fact in 2024, we had 18 five 10-K approvals here in the U S and 45 outside of the U S across our portfolio and what gives US confidence is this combination of having best in class implants with truly differentiated enabled technology, such as <unk> and our <unk>.
Joanne Wuensch: Portfolio, we believe we're going to see continued performance on the back of our focus on anterior approach both with actis villas and concise 2.0 in knees, we have seen a slowdown in revisions where I think you know we are historically number one but feel very confident about continued momentum in primary with the combination of attune and develops which is now available.
Joanne Wuensch: In 30 markets, we have 110000 procedures and as you probably know we're now launching the villas of Uni knee.
Joanne Wuensch: In the AR in the coming quarters and trauma. This was a standout quarter for us close to seven 3% operational growth. When you account for the one timers and this was driven by tremendous uptake of our volt plating system and the feedback we've gotten from surgeons, especially for our small frag, how many frac ing that distal radius has been exceptional I think you also know that spine has been up.
Joanne Wuensch: Been a bit of a laggard for us in the auto portfolio. We are now effectively launching the trial to spine system, which is a thorough columbia system, coupled with Vela spine also launching in a couple in the in the coming quarters and so not the best start with strong confidence in improved performance for the remainder of the year and all of them.
Speaker Change: Thank you. Your next question today is coming from formal dividend from Guggenheim Partners. Your line is now live.
Speaker Change: Great. Thanks for taking the questions and for all the information. So I was just wondering maybe you could focus on that slide 29, Joe that you talked about this for you Joe or for for Jennifer I. Appreciate you sharing your perspectives on those products and how they differ your expectations.
Sensus, there's three projects that are not on there anymore that were there at the end of 2023 that's convicted TV take daily.
Speaker Change: And I don't think that consensus expectations have changed for those very much. Since then so maybe you can just talk about what has changed there why those aren't listed.
Speaker Change: Anything changed from your internal perspectives or or I get externally that just had to come off of that list. Thank you.
Speaker Change: Hi, This is Jeff, yes, you're absolutely correct on the multiple myeloma portfolio was on the slide during the ETR in 2023, and they are not on the slide today, not saying that there is not still a disconnect but it's just not to the extent of the other products on the left at that time, we had estimated.
Speaker Change: If you did the math on the slide it would've been about $4 billion that would have been added to 2027 around 2 billion was added. So those estimates did go off at that time again not that there's not still a disconnect. Its just not to the extent of the others on the side because of those estimates were.
Speaker Change: Increased so.
Speaker Change: Just to be Super clear on that will involve all of we are still extremely bullish based on the clinical progression R&D as well as the performance that we're seeing in the marketplace. I mean look at a car victory I think doubled sales year on year. So it's just a matter of that.
Speaker Change: You guys took your numbers up and so we agree I guess is maybe the best way to say that.
Speaker Change: Maybe just to add in a little bit more on car victim. So yeah over 100% operational growth in the fourth and the first quarter and we continue to make very strong share gains in that second line plus am indication. We continue to add sites, we continue to add countries and capacity.
Speaker Change: Expansion globally, and so we have very firm conviction in Harvick D. S. A $5 billion plus asset and really are rolling that out globally very effectively at this point in time. So we don't see capacity as a constraint going forward based on the strength of the efforts that have taken place and so we're full speed ahead for <unk>.
Speaker Change: Going forward.
Speaker Change: With a towel John here you know, we're really just getting started.
Speaker Change: You've probably seen from our recent data where we've even combine those two molecules to achieve really unprecedented levels of the complete responses.
Speaker Change: At the hematology meetings last year, we also showed combined either tech or Tyler.
Speaker Change: Darcy legs, and demonstrating really impressive hunter versus 100% minimal residual disease negativity in earlier lines of therapy and the opportunity therefore to really start bringing these first in class Bispecific T cell redirecting molecules into earlier lines even frontline.
Speaker Change: In combination with our doors of legs. So really a enormous opportunity lies ahead of us with the check in pill and couple of other things on tech in town. So we continue to expand we've got very good penetration in the academic settings, right now and we continue to expand out into the community we've got very strong.
Speaker Change: New patient starts I know that the products have been plagued a little bit because the products. So effective with some less frequent dosing as we move forward, we should be lapping that soon and really you'll see the strength of those new patient starts and the continued expansion into the community was starting to show through combined downwards, but John talked about in terms of.
Speaker Change: Additional combinations and such we've got very strong convictions remain convinced on the opportunities for tech and talent.
Speaker Change: Thank you next question is coming from Matt mixing from Barclays. Your line is now live.
Speaker Change: Great. Thanks, so much for taking the question.
Speaker Change: I appreciate all the color.
Speaker Change:
Speaker Change: And the question, it's a good question for them.
Speaker Change: Would be great. If you could maybe flesh out the way that.
Speaker Change: The opportunity syndrome by you know.
Speaker Change: Which is now kind of leaning into like.
Speaker Change: And the emerging opportunities for Kendra.
Speaker Change: Laurel.
Speaker Change: You see them coming together.
Speaker Change: Your next year you're after.
Speaker Change: Kind of a portfolio.
Speaker Change: Yeah.
Speaker Change: And then clarification.
Speaker Change: Just for Jim It sounded like when you were describing the ortho and bags.
Speaker Change: Something like 2%, but if you look at the hip and knee, but yeah I'm right to think about.
Speaker Change: 2% in U S. I, just want to make sure I understand it sounded like your your view was that that share that I know.
Speaker Change: You know and we're going to remedy that with with innovations and new products. This year maybe.
Speaker Change: Maybe just could you sort of a point on it but that's not market growth like to parse out like they were below market, we should be doing better or do you or do you think that you know.
Speaker Change: That's kind of where the market's at isn't that like low single digit range for U S.
Speaker Change: How much of an apology for the long long clarification, but super helpful. Thanks.
Speaker Change: Matt Let me start with your question on on on Ortho and to be perfectly Frank while we have seen an improvement in our performance both in hips and knees through 2020 for Q1, clearly wasn't our strongest quarter.
Speaker Change: And so we have seen competitive pressures as you know these are highly attractive categories within earth within ortho, it's where the primarily fighters.
Speaker Change: And frankly, we need to do better and so we believe that our performance. So far in the quarter was slightly below market. These are attractive markets. We've seen a strong robust procedures across all suddenly expect that to continue as I mentioned with the addition of our portfolio of both implants as well as enabling technologies technology.
Speaker Change: Across hips and knees were confident that we will see an improvement through the remaining quarters. Thank you.
Speaker Change: Great. So let's switch over to the Trump fire and immunology and Trumpf I really had a great quarter in the first quarter with sales nearly $1 billion and over 20% operational growth and this was really driven by market share gains in psoriasis and psoriatic arthritis, as well as what we're seeing as it relates to the launch in ulcerative colitis.
Speaker Change: And also in Crohn's disease. So we are really encouraged by the launch in both of these IBD indications.
Speaker Change: Drumfire is now if we start with with ulcerative colitis and how we're doing in that and then I'll go to Crohn's disease. So in ulcerative colitis from VI is the fastest growing product in the ulcerative colitis market IL 20, threes are the fastest growing class and Trumpf fire has already achieved nearly a 50% share of the.
Speaker Change: I L 23, new patient starts and you see so this is really based on the strength of the profile of the product and the strong differentiation that we have as a dual acting IL 23 are both impacting both IL 23, as well as CD 64, the robust data that we have as it relates to efficacy in remission.
Speaker Change: And then as we get into Crohn's disease in the later and ulcerative colitis as well on what we see is unrivaled simplicity with the opportunity for sub Q induction.
Speaker Change: As well as maintenance dosing and when you take a look at our market research data and intent to prescribe. The data comes through really strong that gastroenterologist really prefer drumfire over at the IL 23 competitors based on those aspects that I just discussed so you know efficacy sustained remission and.
Speaker Change: Mucosal healing right now for you see on Crohn's, there is very significant enthusiasm around our launch there and its really quickly getting traction in the first few weeks since approval in Crohn's disease patient initiation volumes are outpacing the other IL 23 launches in the market.
Speaker Change: And the polling.
Speaker Change: Polling tattered a recent market research on the 82% of Gastroenterologists considered Trump fires induction dosing and flexibility to be a very positive differentiation in their treatment decisions and they're seeing the efficacy profile to be quite compelling compared to the other therapies that are in the market. So we believe.
Speaker Change: In IBD, both in ulcerative colitis, and Crohn's. So we're off to a strong start and as a reminder, tracking back just a lora I'm still at 75% of sales were in IBD indications. We see no reason why transpire wouldn't be the same or even better based on what we're seeing with the <unk>.
Speaker Change: And competitiveness of the profile.
Speaker Change: And maybe just a comment on our coach broken road since you asked.
Speaker Change: Asked about but the.
Speaker Change: The most proximal opportunity there is our psoriasis campaign, where we will have altogether five phase III studies data for that this year, we expect to submit this year for psoriasis. We're so excited to be able to offer patients more choice you know with even a.
Speaker Change: A market like psoriasis, which you know is should be well penetrated by now because it is a place where some of the biologics first got their start more than half of patients who were eligible for an advanced therapy are still not an advanced therapy.
Speaker Change: For many of these patients its really an aversion to the injections in growing the biologics route so to be able to offer patients a choice of a once a day pill to provide a solution for their disease, which has efficacy.
Speaker Change: Him ballpark is the biologics and with that well proven safety profile of burial twenty-three class is really exciting for us.
Speaker Change: Yeah, we really believe that I co chicken right and it's a big market expansion opportunity to get in those earlier, if there and lines of therapy and to bring patients into therapies that have that strong biologic like efficacy. We think that there is a lot of room for both I coach Rick Henry and Trump fire in the market.
Speaker Change: And based on different patient needs different physician needs as well and so we think both of these are very important growth drivers for us going forward.
Speaker Change: Thank you, Matt Kevin we have time for one last question.
Speaker Change: Our final question today is coming from Tim Anderson from Bank of America. Your line is now live.
Speaker Change: Well. Thank you so much going back to the tariffs are.
Speaker Change: Our big concern by investors is how that might ultimately wrap and transfer pricing structures and every company I know is usually hesitant to talk about that I'm wondering what J&J can offer up on that front that could include things like major products, where you have transfer price structures in place.
Speaker Change: As well as which geographies you have those in place as well.
Speaker Change: Yeah I appreciate the question to them, it's just not something that for competitive reasons, we're going to comment on.
Speaker Change: I would reiterate what I said before with our $55 billion investment plan at the completion of that plan, which we are.
Speaker Change: Spoke about four years or what advance made these things without using the U S will be minor factor here in the U S.
Speaker Change: So that's how we're planning that's why we believe it's important to provide discontinuity as I said before.
Speaker Change: After 2017, prescient trumps tax reform the level of investments in the U S. Having increase and we plan to continue to increase it given the current tax regime on improvements that may come into the future.
Speaker Change: Thank you, Tim and thanks to everyone for your questions and your continued interest in our company, we apologize to those we couldn't get to because of time, but don't hesitate to reach out to the investor relations team with any remaining questions that you may have.
Speaker Change: As many of you have seen Darrin snelgrove will be transitioning into the Investor relations role starting may 1st as I transition into the innovative medicine CFO role.
Speaker Change: The last three and a half years have been an absolute pleasure getting to engage with you all.
Joaquin Duato: I will now turn the call over to Joaquin for some brief closing remarks. Thank you Jess and thank you everyone for joining the call today.
Speaker Change: As you heard 2025, it's going to be cut.
Speaker Change: G or for Johnson <unk> Johnson.
Speaker Change: With our Q1 results we are off to a great start.
Speaker Change: These are startup reflects the power of Johnson <unk> Johnson's uniquely diversified business model.
Speaker Change: Further strengthens our confidence in our 2025 guidance ambition. Thank you very much.
Speaker Change: Thank you. This concludes today's Johnson <unk> Johnson's first quarter 2025 earnings Conference call you may now disconnect.
Speaker Change: Okay.